A Phase I/II, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients With Advanced Solid Tumours.
Phase of Trial: Phase I/II
Latest Information Update: 10 Jul 2012
At a glance
- Drugs AZD 8055 (Primary)
- Indications Endometrial cancer; Lymphoma; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 01 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Feb 2011 Actual end date (November 2010) added as reported by ClinicalTrials.gov.